Iparomlimab

艾帕洛利单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameIparomlimab
Drug Alias NameQL1604QL-1604PSB-103
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-PD-1
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsSolid tumoursUterine Cervical NeoplasmsSmall Cell Lung Carcinoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesQilu Puget Sound Biotherapeutics Corp
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTianjin Medical University Cancer Institute And HospitalXinhua Hospital Affiliated To Shanghai Jiaotong University School Of MedicineQilu Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursSmall Cell Lung CarcinomaLiver Neoplasms +[6] 
Inactive IndicationsUterine Cervical NeoplasmsAdenocarcinomaNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A